The Promise of Gene Therapy

With phase 3 topline data for sura-vec expected later this year, Arshad M. Khanani, MD, FASRS, reflects on how gene therapy could transform long-term treatment for nAMD.

By: Arshad M. Khanani, MD, MA, FASRS

Retinal Physician July 20, 2026

Clinical Scorecard: The Promise of Gene Therapy

At a Glance

Category	Detail
Condition	wet age-related macular degeneration (nAMD)
Key Mechanisms	Gene therapy delivered subretinally as a drug delivery platform
Target Population	Patients with wet age-related macular degeneration
Care Setting	Clinical practice for long-term treatment

Key Highlights

Phase 3 topline data for sura-vec expected later this year
RGX-314 (sura-vec) shows potential to reduce treatment burden
Gene therapy could transform long-term treatment for nAMD
First pivotal gene therapy program designed for nAMD
Real-world treatment outcomes are inferior to clinical trials

Guideline-Based Recommendations

Diagnosis

Management

Consider gene therapy for reducing treatment burden in nAMD

Monitoring & Follow-up

Risks

Patient & Prescribing Data

Patients with chronic injections for nAMD

Potential for large subset of patients to avoid further injections after one subretinal gene therapy injection

Clinical Best Practices

Implement gene therapy in clinical practice to optimize long-term outcomes

PentaVision

Retinal Physician